Skip to main content

Chuanxiong-type preparations for acute ischemic stroke

Also available in

Stroke is a common disorder. It is due either to blockage of an artery in the brain or to bleeding in the brain. Chuanxiong is a Traditional Chinese Medicine. It is widely used in China for the treatment of patients with stroke. Two poor quality trials involving 161 participants were included in this review. The authors did not find any strong evidence about its effects. Well-designed and conducted trials will be needed to provide reliable evidence to show whether this intervention does more good than harm.

Background

Stroke, 88% of which are ischemic, is a common cause of death and disability all over the world. Chuanxiong has been reported to be beneficial in treating stroke. However, the strength of evidence to support its use is unclear.

Objectives

To assess the safety and efficacy of chuanxiong for acute ischemic stroke.

Search strategy

We searched the Cochrane Stroke Group Trials Register (last searched January 2008), the Chinese Stroke Trials Register (last searched December 2007), the trials register of the Cochrane Complementary Medicine Field (last searched December 2007), the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 4, 2007), MEDLINE (1966 to December 2007), EMBASE (1980 to December 2007), CNKI (1979 to December 2007), AMED (1985 to December 2007) and CBM-disc (1979 to December 2007). We also handsearched appropriate journals and relevant conference proceedings and searched ongoing trials and research registers.

Selection criteria

All randomised controlled trials comparing the clinical outcomes of chuanxiong with placebo or no treatment in patients with acute ischemic stroke (within 14 days of onset).

Data collection and analysis

Two review authors independently selected trials for inclusion, four review authors interviewed study authors to confirm randomisation, and two review authors assessed trial quality, extracted and analysed data.

Main results

Two trials involving 161 participants were included. Both trials were of low quality. Neither of the trials reported the mortality rate or dependency of the participants and no reliable evidence is available in this review.

Authors' conclusions

In the two poor quality trials published, there is insufficient evidence to suggest any clinical recommendations. Well-designed and performed high-quality trials are needed.

Citation
Yuan Y, Zeng X, Luo Y, Li Z, Wu T. Chuanxiong-type preparations for acute ischemic stroke. Cochrane Database of Systematic Reviews 2022, Issue 3. Art. No.: CD005569. DOI: 10.1002/14651858.CD005569.pub2.

Our use of cookies

We use necessary cookies to make our site work. We'd also like to set optional analytics cookies to help us improve it. We won't set optional cookies unless you enable them. Using this tool will set a cookie on your device to remember your preferences. You can always change your cookie preferences at any time by clicking on the 'Cookies settings' link in the footer of every page.
For more detailed information about the cookies we use, see our Cookies page.

Accept all
Configure